Discover Great Companies Discover Great Clients
Companies Salaries Jobs
Jobs |
Jobs Companies Salary Majors

Company Overview

About the Company

万春宏基(大连)医药有限公司是SEED Therapeutics全资子公司。

SEED Therapeutics位于美国宾夕法尼亚州普鲁士国王的科学城,专注于研发用于突破性治疗的新型“分子胶”(MG)。
多元化和快速发展的内部管线:目前开发了8个项目,涵盖肿瘤学、神经退行性疾病、免疫学和抗病毒适应症,其中包括6个内部项目,涉及5个新型E3s。
1. 主导项目是RBM39口服降降剂(用于生物标志物选择的肝癌、结肠癌、前列腺癌、神经母细胞瘤等),预计在2025年下旬实现FHD。
2. 神经退行性疾病项目降解Tau蛋白治疗阿尔茨海默病,目前具有细胞活性,将在2025年底左右达到IND候选状态。

Expand
Information is aggregated from the web and may not be exact. For reference only.
Information incorrect? Claim this company to edit

Recruitment Overview / Current Status (3 open positions)

Manage
Note: How fast is hiring at 万春宏基(大连)医药有限公司 growing? . A rising curve may indicate expansion; a falling curve may indicate slower growth or good retention. Based on publicly available data, for reference only.

Related Industry Tags

Tags are auto-annotated by keyword text matching and may be correlated. For reference only.

Business Registration

Provided by

Operating Status: 开业
Registered Capital: 1,000万(元)
Legal Representative: 贾林庆
Date Established:
Credit Code: 91210213MA7LPQ8N5F
Registered Address: 中国(辽宁)自由贸易试验区大连经济技术开发区双D港双D4街19-6

Report

*Reason:

Radical political or ideological topics
Advertising or spam
Pornographic or vulgar content
Obscene language or personal attacks
Other

Congratulations, submitted successfully!

Your edit is under review. You will be notified by email within 1 business day.

Submission failed.

Followed successfully. We'll notify you of any company updates.

Help others learn about this company, add my impression of this company»

Log in with the following accounts to save your follows

Followed successfully, we'll notify you of any company updates

出国移民
客服
由百度提供